A hypnotic is a psychoactive substance whose primary clinical action is to induce or sustain sleep, accompanied by sedation, anxiolysis, and progressively deeper central nervous system depression as exposure rises.[1]
The grouping is defined by this functional outcome — sleep promotion — rather than by any shared chemical scaffold, and its boundary with the broader sedative category is largely dose-dependent: an agent that calms at lower exposures typically induces sleep at higher ones.
Membership spans at least four chemically unrelated families: the classical benzodiazepines (temazepam, flunitrazepam, flunitrazolam), the nonbenzodiazepine "Z-drugs" (zolpidem, zopiclone, eszopiclone), the short-acting barbiturates (pentobarbital, secobarbital), and the quinazolinone derivative methaqualone. Despite this structural diversity, all members converge on enhancement of GABA-A receptor–mediated inhibition.
Across the class, effects deepen with exposure, from anxiolysis and mild sedation at low doses, through marked drowsiness and anterograde amnesia in the sleep-inducing range, to deep sedation, loss of airway reflexes, and respiratory depression at supratherapeutic levels.[1] Hypnotics are used clinically for short-term insomnia, procedural sedation, and anesthesia induction; several members are also misused recreationally, and some carry a history of involvement in drug-facilitated assault.
Pharmacology
Most hypnotics converge on a single endpoint — enhanced GABA-A receptor–mediated inhibition — by binding distinct allosteric sites on the same chloride-permeable ion channel.[1] GABA-A activation hyperpolarizes neurons and reduces their probability of firing; the class's members differ in where they bind and how they shape channel gating, but they share the consequence.
| Binding site | Representative members | How it reaches the shared endpoint |
|---|---|---|
| Benzodiazepine site (α/γ subunit interface) | Benzodiazepines (temazepam, flunitrazepam, flunitrazolam) and Z-drugs (zolpidem, zopiclone, eszopiclone) | Positive allosteric modulation: increases the frequency of chloride channel opening in the presence of GABA; Z-drugs preferentially target α1-containing receptors, which biases their profile toward sedation[2] |
| Barbiturate transmembrane site | Pentobarbital, secobarbital | Prolongs the duration of chloride channel opening; at high concentrations directly gates the channel without GABA, removing the natural ceiling on inhibition[3] |
| Distinct β(+)/α(−) transmembrane interface | Methaqualone | Positive allosteric modulation across most α/β/γ subunit combinations, with variable activity at δ-containing extrasynaptic receptors[4] |
The mechanistic detail matters less for safety than the shared endpoint. Whether a member increases the frequency of channel opening, prolongs its duration, or directly gates the channel at high exposure, the net effect on brainstem arousal and respiratory drive is additive — which is why combining hypnotics with each other, with alcohol, or with opioids amplifies depression of breathing far beyond any single agent.
A second consequence of the shared receptor system is class-wide cross-tolerance: adaptation to one member reduces sensitivity to all others, and extends to other GABAergic substances including ethanol.[5] Extrasynaptic GABA-A receptors, tonically activated by ambient GABA, contribute to deeper planes of sedation and are modulated by some members of the class but not others.[6]
Substances
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Temazepam | Benzodiazepine | Short-acting hypnotic benzodiazepine widely prescribed for insomnia |
| Flunitrazepam | Benzodiazepine | High-potency hypnotic notable for pronounced anterograde amnesia; historical involvement in drug-facilitated assault |
| Flunitrazolam | Triazolobenzodiazepine | Extremely high-potency designer benzodiazepine with limited clinical literature |
| Zolpidem | Z-drug (imidazopyridine) | α1-preferring hypnotic associated with complex sleep behaviours such as sleep-driving and sleep-eating |
| Zopiclone | Z-drug (cyclopyrrolone) | Racemic hypnotic; the S-enantiomer is marketed separately as eszopiclone[7] |
| Eszopiclone | Z-drug (cyclopyrrolone) | S-enantiomer of zopiclone with a longer half-life, approved for chronic insomnia treatment |
| Pentobarbital | Barbiturate | Short-acting barbiturate used in procedural sedation, anesthesia induction, and physician-assisted dying protocols |
| Secobarbital | Barbiturate | Short-acting hypnotic barbiturate largely displaced by benzodiazepines from the 1970s onward[3] |
| Methaqualone | Quinazolinone | Initially marketed as a safer alternative to barbiturates; later controlled after recognition of high misuse potential and severe withdrawal |
These members differ in subunit selectivity, kinetics, and clinical context, but each induces sleep through enhanced GABAergic inhibition and each contributes to the class's shared depressant load when combined with other CNS-active substances.
Subjective Effects
The subjective trajectory tracks a single axis — deepening GABAergic inhibition — as exposure rises.
| Exposure | Characteristic effects |
|---|---|
| Low | Anxiolysis, mild sedation, muscle relaxation, behavioural disinhibition, and reduced psychomotor precision |
| Moderate–high (sleep-inducing range) | Marked drowsiness progressing to sleep, slurred speech, ataxia, and anterograde amnesia — failure to encode new memories from the time of administration |
| High | Deep sedation, hypotension, loss of protective airway reflexes, dose-dependent respiratory depression, and coma |
Subjective character differs somewhat across subgroups — benzodiazepines feel more anxiolytic and muscle-relaxant at low doses, Z-drugs at therapeutic doses feel more selectively sedating — but the deep-sedation profile converges at higher exposures. Because the same physiological axis drives both the sought-after sleep induction and the dangerous suppression of breathing, the margin between hypnosis and life-threatening depression narrows as exposure rises and narrows further whenever any other depressant is added.
Safety
Risk profile
The defining acute danger of the hypnotic class is dose-dependent respiratory depression, and the danger rises sharply in combination. Combining a hypnotic with another CNS depressant — opioids, alcohol, or a second GABAergic agent — produces additive suppression of brainstem respiratory drive and accounts for the majority of hypnotic-related overdose deaths.[8]
Risk is not uniform within the class. Barbiturates such as pentobarbital and secobarbital carry the highest single-agent overdose lethality, because at high concentrations they directly gate the chloride channel without GABA — removing the natural ceiling that protects benzodiazepine and Z-drug overdoses.[3]
Benzodiazepines and Z-drugs taken alone are comparatively safer in single-agent overdose, but that margin collapses in polysubstance contexts: epidemiological synthesis finds that the great majority of overdose patients with benzodiazepine-agonist prescriptions died in combination with opioids or other depressants.[8]
Beyond overdose, the class impairs balance, coordination, and reaction time well into the day following a nighttime dose, contributing to documented increases in falls and motor vehicle accidents. Anterograde amnesia is a consistent class effect and is particularly pronounced with flunitrazepam and zolpidem; with zolpidem and other Z-drugs it can manifest as complex sleep behaviours — sleep-driving, sleep-eating, and other actions the person does not later recall.
The 2021 US National Survey on Drug Use and Health reported that roughly 4.9 million people aged 12 or older had misused prescription tranquilizers or sedatives in the past year, with the highest rates among young adults.[9]
Practical harm-reduction points apply across the class: hypnotics should not be combined with other depressants outside medical supervision; flumazenil reverses benzodiazepine and Z-drug effects but can precipitate seizures in dependent individuals and does not reverse barbiturate or methaqualone toxicity; naloxone reverses opioid contributions to a mixed overdose but does not reverse the GABAergic component.
Tolerance & dependence
Tolerance to the hypnotic effects of this class develops with regular use and typically appears faster than tolerance to anxiolytic or anticonvulsant effects. The underlying neuroadaptation involves downregulation of GABA-A receptor density, uncoupling between the benzodiazepine and GABA binding sites, and subunit-composition shifts that reduce receptor sensitivity.[5] The same adaptations leave the brain in a state of compensatory hyperexcitability that is exposed whenever the drug is removed.
Physical dependence is a class-wide property and is documented for benzodiazepine, Z-drug, barbiturate, and methaqualone members; cross-tolerance and cross-dependence between members are the rule rather than the exception.[5]
Recovery
Recovery from hypnotic dependence is achievable and is well-trodden clinical territory. The standard approach is a medically supervised taper, typically by substituting a long-acting GABAergic agent such as a long-acting benzodiazepine or phenobarbital and reducing the dose gradually at a rate matched to the individual's dependence severity and clinical response.[10]A protracted phase of anxiety, sleep disruption, and mood instability can persist for weeks to months after the acute taper; cognitive-behavioural therapy for insomnia (CBT-I) is the most evidence-supported long-term alternative to pharmacological sleep aids for the underlying sleep problem. If you or someone you know is dependent on a hypnotic, a clinician or a withdrawal-management service can structure a safe taper.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1] ^abcWinsky-Sommerer, R. (2009) Role of GABAA receptors in the physiology and pharmacology of sleep — European Journal of Neuroscience doi:10.1111/j.1460-9568.2009.06716.x
- [2] ^Richter, G. and Liao, V.W.Y. and Ahring, P.K. and Chebib, M. (2020) The Z-Drugs Zolpidem, Zaleplon, and Eszopiclone Have Varying Actions on Human GABAA Receptors Containing γ1, γ2, and γ3 Subunits — Frontiers in Neuroscience doi:10.3389/fnins.2020.599812
- [3] ^abcLópez-Muñoz, F. and Ucha-Udabe, R. and Alamo, C. (2005) The history of barbiturates a century after their clinical introduction — Neuropsychiatric Disease and Treatment PMID:18568113
- [4] ^Hammer H, Bader BM, Ehnert C, Bundgaard C, Bunch L, Hoestgaard-Jensen K, Schroeder OH, Bastlund JF, Gramowski-Voss A, Jensen AA (2015) A Multifaceted GABAA Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude) — Molecular Pharmacology doi:10.1124/mol.115.099291
- [5] ^abcLicata, S.C. and Rowlett, J.K. (2008) Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond — Pharmacology Biochemistry and Behavior PMID:18295321
- [6] ^Orser, B.A. (2006) Extrasynaptic GABAA receptors are critical targets for sedative-hypnotic drugs — Journal of Clinical Sleep Medicine PMID:17557502